Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?
作者信息
Landi Lorenza, Cappuzzo Federico
机构信息
Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100 Livorno, Italy.
出版信息
J Thorac Dis. 2012 Apr 1;4(2):226-8. doi: 10.3978/j.issn.2072-1439.2012.03.14.
Abstract
摘要
相似文献
1
Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?针对携带EGFR突变的欧洲患者的最佳一线治疗：经度和种族有影响吗？
J Thorac Dis. 2012 Apr 1;4(2):226-8. doi: 10.3978/j.issn.2072-1439.2012.03.14.
2
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.一线 EGFR-TKI 治疗后含敏感 EGFR 突变的老年非小细胞肺癌患者接受细胞毒药物化疗的疗效和安全性。
Cancer Chemother Pharmacol. 2018 Jul;82(1):119-127. doi: 10.1007/s00280-018-3596-6. Epub 2018 May 8.
3
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.根据 EGFR 和 K-RAS 突变状态，接受一线化疗的非小细胞肺癌患者的临床结局。
Lung Cancer. 2010 Jul;69(1):110-5. doi: 10.1016/j.lungcan.2009.09.010. Epub 2009 Oct 24.
4
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.EGFR-TKI 重挑战治疗在携带药物敏感 EGFR 突变的老年晚期非小细胞肺癌患者中的疗效和安全性。
Medicina (Kaunas). 2021 Sep 3;57(9):929. doi: 10.3390/medicina57090929.
5
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?对罕见表皮生长因子受体突变L861Q和S768I的各种表皮生长因子受体酪氨酸激酶抑制剂的敏感性：最佳表皮生长因子受体酪氨酸激酶抑制剂是什么？
Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14.
6
Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.一线 EGFR 酪氨酸激酶抑制剂治疗携敏感 EGFR 突变的老年非小细胞肺癌患者的后进展生存对总生存的临床影响。
Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14.
7
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.表皮生长因子受体基因突变的非小细胞肺癌患者一线使用吉非替尼治疗后复发时使用吉非替尼联合培美曲塞的 II 期临床试验。
Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.
8
Erlotinib in the first-line treatment of non-small-cell lung cancer.厄洛替尼用于非小细胞肺癌的一线治疗。
Expert Rev Anticancer Ther. 2013 May;13(5):523-33. doi: 10.1586/era.13.23.
9
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors.一线酪氨酸激酶抑制剂治疗伴有罕见表皮生长因子受体突变的老年IV期肺腺癌患者可获得更好的无进展生存期
Cancers (Basel). 2018 Nov 13;10(11):434. doi: 10.3390/cancers10110434.
10
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.携多个分子改变的肺癌患者的特征和结局：IFCT 研究生物标志物法国部分的结果。
J Thorac Oncol. 2017 Jun;12(6):963-973. doi: 10.1016/j.jtho.2017.02.001. Epub 2017 Feb 9.
本文引用的文献
1
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.First-SIGNAL：一线单药易瑞沙对比吉西他滨和顺铂治疗从不吸烟肺腺癌的临床试验。
J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.
2
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
3
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
4
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
5
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
6
Screening for epidermal growth factor receptor mutations in lung cancer.肺癌中表皮生长因子受体突变的筛查
N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.
7
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
8
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.一项关于晚期非小细胞肺癌的国际多中心随机III期研究：一线使用厄洛替尼序贯二线使用顺铂/吉西他滨与一线使用顺铂/吉西他滨序贯二线使用厄洛替尼的对比——TORCH试验的治疗原理及方案动态
Clin Lung Cancer. 2008 Jul;9(4):235-8. doi: 10.3816/CLC.2008.n.037.
9
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
Zotero 插件